June 5, 2017 / 11:06 AM / 2 months ago

BRIEF-Can-Fite establishes clinical advisory board for NAFLD/NASH

1 Min Read

June 5 (Reuters) - Can Fite Biopharma Ltd

* Can-Fite establishes clinical advisory board for nafld/nash

* Can Fite Biopharma - clinical advisory board comprised of experts in treatment of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)

* Can Fite Biopharma Ltd- a phase ii trial of namodenoson in treatment of nafld/nash is expected to commence patient enrollment during q3 of 2017. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below